Results 81 to 90 of about 4,142 (167)

Guselkumab in Inflammatory Bowel Disease: Mechanism, Clinical Efficacy, Safety, and Treatment Positioning. [PDF]

J Clin Med
White L, Sharma E, Limdi J, Din S, Patel K, Honap S.   +5 more
europepmc   +1 more source

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial. [PDF]

Inflamm Bowel Dis
Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators .   +17 more
europepmc   +1 more source

Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis. [PDF]

J Inflamm Res
D'Amico F, Fanizzi F, Magro F, Dignass A, Gutiérrez Casbas A, Verstockt B, Hart A, Armuzzi A, Jairath V, Peyrin-Biroulet L, Danese S.   +10 more
europepmc   +1 more source

Interstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review. [PDF]

Pulm Ther
Castelli G, Fiorentù G, Maggioni G, Bellani S, Giulianelli G, Bernardinello N, Cocconcelli E, Pezzuto F, Polverosi R, Calabrese F, Spagnolo P, Balestro E.   +11 more
europepmc   +1 more source

Guselkumab: Pediatric First Approval

Pediatric Drugs
Guselkumab (TREMFYA®) is a fully human IgG1λ monoclonal antibody developed by Johnson & Johnson to selectively target the p19 subunit of interleukin (IL)-23, a cytokine that plays a key role in various immune-mediated inflammatory diseases. Guselkumab is approved in multiple countries worldwide, including the USA and those of the EU, for the treatment ...
openaire   +3 more sources

Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates. [PDF]

Cureus
Migdady DS, Alshyyab N, Alkhalaileh HM, Goh ZY, Reingold Y, Rababah O, Zghayer TM, Alsalhi Y, Alsaidi AK, Alrabbai MG.   +9 more
europepmc   +1 more source

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage. [PDF]

Clin Pract
Bernardini N, Marotta G, Skroza N, Graceffa D, Bragazzi MC, Finistauri Guacci L, Tolino E, Sasso FP, Gallo U, Richetta AG, Dattola A.   +10 more
europepmc   +1 more source

Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). [PDF]

J Psoriasis Psoriatic Arthritis
Strober B, Augustin M, Tada Y, Parnell Lafferty K, Krol Y, Skobelev E, Ibrahim F, Fakharzadeh S, Gniadecki R.   +8 more
europepmc   +1 more source

Targeting the IL-23 pathway in inflammatory bowel disease: from cytokine inhibition to oral IL-23 receptor blockade. [PDF]

eGastroenterology
Honap S, Colwill M, Dignass A, Jairath V, Magro F, Danese S, Peyrin-Biroulet L.   +6 more
europepmc   +1 more source

Guselkumab as a therapeutic option for recalcitrant pyoderma gangrenosum and Crohn disease: a case report and review of the literature. [PDF]

Skin Health Dis
Tanrıbilir ME, Atliya O, Karakan T, Adışen E.   +3 more
europepmc   +1 more source